ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

摘要:

One of the most difficult challenges that policy-makers will face in the next 10 years is tackling the ethical considerations involved in the coverage of so-called ‘lifestyle’ drugs. Should health plans provide coverage for such drugs? If so, should limits be set? And will limits jeopardise physician-patient relationships? At the sixth annual Drug Information Association symposium on Quality of Life Evaluation [Hilton Head, South Carolina, US; March 1999], Dr James Sabin shared his experience in establishing coverage policies and provided some answers to these questions.*

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

摘要:

Hepatitis C virus (HCV) is a very significant pathogen and may be the biggest healthcare problem facing the world over the next decade. Interferon (IFN) is the standard therapy for HCV infection and most patients have an initial response rate of 40-50%. But unfortunately, sustained response rates are very poor, reaching no more than 10-20%. According to Dr Graham Foster from St Mary's Hospital, London, UK, standard IFN simply isn't good enough. A new IFN is needed for the treatment of HCV infection, and Dr Foster believes that PEG IFN-&agr;-2a [‘Pegasys’] may be a promising new option. He released interim results from a study of PEG IFN-&agr;-2a in patients with HCV infection at a Roche-sponsored satellite symposium at the 34th Annual Meeting of the European Association for the Study of the Liver [Naples, Italy; April 1999].

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS

摘要:

The once daily non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz was recently recommended for inclusion in the HIV infection treatment guidelines of the US Department of Health and Human Services (DHHS) as a preferred agent for treatment of established HIV infection in combination with 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs).*This is the first time the panel has recommended a protease inhibitor-sparing combination containing a NNRTI as a first-line treatment option. New data presented at the 9th European Congress of Clinical Microbiology and Infectious Diseases [Berlin, Germany; March 1999] confirm these recommendations. There are currently no data showing that efavirenz can reduce transmission of HIV through blood contamination or sexual contact. However, data presented for the first time at the conference show that efavirenz reduces levels of HIV in the genital tract of women.

ISSN:1173-8324    

出版商:ADIS    

年代:1999

数据来源: ADIS